AEON Biopharma, Inc.

AEON Biopharma, Inc. (ticker: AEON) is a clinical-stage biopharmaceutical company that entered the public markets through its business combination with Priveterra Acquisition Corp, a SPAC that completed its IPO in 2021. The company operates in the therapeutics sector, with a pipeline centered on botulinum neurotoxin-based treatments targeting neurological and movement disorders. AEON filed an 8-K with the SEC on June 13, 2025, under accession number 0001837607-25-000059, reflecting ongoing disclosure obligations as a post-combination public company. The company's current status is that of a listed post-merger entity continuing its clinical development programs. Sign up for full data, filings history, and sponsor analytics on SpacDesk.